Rubius Therapeutics (NASDAQ:RUBY) Price Target and Consensus Rating
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
5 Wall Street analysts have issued ratings and price targets for Rubius Therapeutics in the last 12 months. Their average twelve-month price target is $13.25, predicting that the stock has a possible upside of 5.49%. The high price target for RUBY is $28.00 and the low price target for RUBY is $4.00. There are currently 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus rating of "Hold."
Rubius Therapeutics (NASDAQ:RUBY) Consensus Price Target History
Average Share Price and Price Target by Month
The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Rubius Therapeutics (NASDAQ:RUBY) Analyst Ratings History
Show:
(Data available from 3/6/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
